Breaking News Instant updates and real-time market news.

GMXAY

Genmab

$0.00

(0.00%)

, JNJ

Johnson & Johnson

$140.79

0.24 (0.17%)

15:32
07/08/19
07/08
15:32
07/08/19
15:32

Genmab says Phase II GRIFFIN study met primary endpoint

Genmab (GMXAY) announced that topline data from the Phase II GRIFFIN study of newly diagnosed patients with multiple myeloma eligible for high-dose chemotherapy and autologous stem cell transplantation, who were treated with daratumumab in combination with lenalidomide, bortezomib, and dexamethasone, met its primary endpoint, demonstrating a higher percentage of stringent complete responses than patients who received VRd alone. Specifically, the topline data showed that 42.4% of patients treated with daratumumab in combination with VRd achieved a sCR, compared to 32.0% of patients who received VRd alone, with an odds ratio of 1.57. Secondary endpoints, including the results of the minimal residual disease analysis, supported the primary endpoint favoring daratumumab in combination with VRd. Overall, the safety profile of daratumumab in combination with VRd was consistent with the safety profile for each therapy separately, which has been reported from previous studies with the VRd regimen as well as previous studies with daratumumab. Further analysis of the safety and efficacy data is ongoing, and Janssen Biotech (JNJ), which licensed daratumumab from Genmab in 2012, plans to submit additional data for presentation at an upcoming medical conference.

GMXAY

Genmab

$0.00

(0.00%)

JNJ

Johnson & Johnson

$140.79

0.24 (0.17%)

  • 16

    Jul

  • 09

    Sep

  • 16

    Sep

GMXAY Genmab
$0.00

(0.00%)

01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Genmab downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Genmab to Neutral with an unchanged price target of FKK 1,150. The analyst believes Darzalex's potential is largely reflected in the shares at current levels.
12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
Genmab upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Genmab to Buy and raised his price target for the shares to DKK 1,250 from DKK 1,220. The analyst says the shares are "well underpinned" by Darzalex while the company's pipeline is maturing.
10/01/18
HCWC
10/01/18
INITIATION
HCWC
Buy
Genmab initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Genmab with a Buy rating and DKK 1,600 price target.
JNJ Johnson & Johnson
$140.79

0.24 (0.17%)

05/30/19
COWN
05/30/19
NO CHANGE
Target $155
COWN
Outperform
Johnson & Johnson weakness may be overdone, says Cowen
Cowen analyst Joshua Jennings noted the State of Oklahoma is claiming Janssen Pharmaceuticals helped fuel the US opioid crisis which then caused volatility in Johnson & Johnson (JNJ) shares. While JNJ maintains its involvement was limited, the analyst says it is challenging to estimate the potential liability. His analysis however suggests, the stock's pullback is overdone. Jennings maintained his Outperform rating and $155 price target on Johnson & Johnson shares.
05/30/19
WELS
05/30/19
NO CHANGE
WELS
Outperform
Johnson & Johnson concerns over opioid case seem 'overblown,' says Wells Fargo
As the first state opioid trial begins in Oklahoma, Wells Fargo analyst Larry Biegelsen continues to believe that litigation will be manageable for Johnson & Johnson given its size and resources. The analyst notes that it appears the company's pain products - Duragesic patch and Nucynta/ER - accounted for less than 1% of the Oklahoma Medicaid opioid prescriptions from 1996-2017, while the company's slides also show data that fentanyl and tapentadol have lower abuse rates and diversion rates versus oxycodone and hydrocodone. Overall, Biegelsen believes concerns over the Oklahoma opioid case "may be overblown." The analyst has an Outperform rating on the shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $163
GSCO
Buy
Johnson & Johnson initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Johnson & Johnson with a Buy rating and $163 price target. J&J's diversified portfolio is a potential strength as it results in the company having the lowest exposure to Medicare/Medicaid within the group, Flynn tells investors in a research note. As a result, he thinks the stock will be less impacted by potential drug pricing headlines/policy proposals ahead of the 2020 presidential election.
05/22/19
WELS
05/22/19
NO CHANGE
WELS
Wells Fargo says start of opioid trial won't be positive for Teva shares
Wells Fargo analyst David Maris noted that the nation's first major opioid case, brought against Teva (TEVA) and Johnson & Johnson (JNJ) in Oklahoma, will begin on May 28 and that the entire trial will be webcast. He thinks that the trial start and the opening webcast statements "will not be positive for Teva shares," adding that he suspects the outcome of this suit will be extrapolated to the Multi-District Litigation coming this fall. Maris keeps a Market Perform rating on Teva shares.

TODAY'S FREE FLY STORIES

TXT

Textron

$54.02

0.59 (1.10%)

06:30
07/17/19
07/17
06:30
07/17/19
06:30
Earnings
Textron reports Q2 EPS 93c, consensus 86c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

SHO

Sunstone Hotel

$13.54

-0.01 (-0.07%)

06:28
07/17/19
07/17
06:28
07/17/19
06:28
Downgrade
Sunstone Hotel rating change  »

Sunstone Hotel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

COP

ConocoPhillips

06:27
07/17/19
07/17
06:27
07/17/19
06:27
Upgrade
ConocoPhillips rating change  »

ConocoPhillips upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

PEB

Pebblebrook Hotel

$27.37

-0.195 (-0.71%)

, HLT

Hilton

$99.87

0.68 (0.69%)

06:27
07/17/19
07/17
06:27
07/17/19
06:27
Downgrade
Pebblebrook Hotel, Hilton, Marriott, Wyndham Hotels & Resorts rating change  »

Pebblebrook Hotel…

PEB

Pebblebrook Hotel

$27.37

-0.195 (-0.71%)

HLT

Hilton

$99.87

0.68 (0.69%)

MAR

Marriott

$143.94

1.17 (0.82%)

WH

Wyndham Hotels & Resorts

$61.20

0.5 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 11

    Sep

  • 12

    Sep

EXLS

ExlService

$65.12

-0.45 (-0.69%)

06:23
07/17/19
07/17
06:23
07/17/19
06:23
Downgrade
ExlService rating change  »

ExlService downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 12

    Aug

GLOB

Globant

$106.97

-0.64 (-0.59%)

06:21
07/17/19
07/17
06:21
07/17/19
06:21
Downgrade
Globant rating change  »

Globant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

MUX

McEwen Mining

$1.72

-0.02 (-1.15%)

06:21
07/17/19
07/17
06:21
07/17/19
06:21
Hot Stocks
McEwen Mining reports Q2 production 45,881 gold equivalent oz. »

McEwen Mining reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$2,010.00

-11 (-0.54%)

06:20
07/17/19
07/17
06:20
07/17/19
06:20
Periodicals
Amazon exec Dave Clark defends company in CNN op-ed »

Dave Clark, Amazon's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 25

    Jul

WORK

Slack Technologies

$34.43

-0.35 (-1.01%)

, MSFT

Microsoft

$137.08

-1.86 (-1.34%)

06:19
07/17/19
07/17
06:19
07/17/19
06:19
Initiation
Slack Technologies, Microsoft, Alphabet, Alphabet Class A initiated  »

Slack Technologies…

WORK

Slack Technologies

$34.43

-0.35 (-1.01%)

MSFT

Microsoft

$137.08

-1.86 (-1.34%)

GOOG

Alphabet

$1,152.97

2.58 (0.22%)

GOOGL

Alphabet Class A

$1,152.86

2.4 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 25

    Jul

  • 25

    Jul

  • 06

    Aug

  • 08

    Aug

  • 27

    Oct

GOOG

Alphabet

$1,152.97

2.58 (0.22%)

, GOOGL

Alphabet Class A

$1,152.86

2.4 (0.21%)

06:18
07/17/19
07/17
06:18
07/17/19
06:18
Periodicals
Google terminating 'Project Dragonfly' censored search engine for China, BI says »

Google is killing the…

GOOG

Alphabet

$1,152.97

2.58 (0.22%)

GOOGL

Alphabet Class A

$1,152.86

2.4 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 25

    Jul

  • 25

    Jul

  • 08

    Aug

  • 27

    Oct

ADBE

Adobe

$305.76

-2.95 (-0.96%)

06:18
07/17/19
07/17
06:18
07/17/19
06:18
Recommendations
Adobe analyst commentary  »

UBS believes Adobe can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$40.57

-1.04 (-2.50%)

06:16
07/17/19
07/17
06:16
07/17/19
06:16
Upgrade
Progress Software rating change  »

Progress Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

GOOGL

Alphabet Class A

$1,152.86

2.4 (0.21%)

, GOOG

Alphabet

$1,152.97

2.58 (0.22%)

06:15
07/17/19
07/17
06:15
07/17/19
06:15
Periodicals
Palantir co-founder Joe Lonsdale calls Google 'unpatriotic,' CNBC reports »

The co-founder of data…

GOOGL

Alphabet Class A

$1,152.86

2.4 (0.21%)

GOOG

Alphabet

$1,152.97

2.58 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 25

    Jul

  • 25

    Jul

  • 08

    Aug

  • 27

    Oct

OMP

Oasis Midstream Partners

$21.78

(0.00%)

06:15
07/17/19
07/17
06:15
07/17/19
06:15
Initiation
Oasis Midstream Partners initiated  »

Oasis Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGE

Tallgrass Energy

06:14
07/17/19
07/17
06:14
07/17/19
06:14
Initiation
Tallgrass Energy initiated  »

Tallgrass Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NGL

NGL Energy Partners

$15.30

0.11 (0.72%)

06:13
07/17/19
07/17
06:13
07/17/19
06:13
Initiation
NGL Energy Partners initiated  »

NGL Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBLX

Noble Midstream

$32.45

-0.3 (-0.92%)

06:13
07/17/19
07/17
06:13
07/17/19
06:13
Initiation
Noble Midstream initiated  »

Noble Midstream initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

IMRN

Immuron

$4.27

1.43 (50.35%)

06:11
07/17/19
07/17
06:11
07/17/19
06:11
Syndicate
Immuron 339.1K share Spot Secondary priced at $4.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

PAA

Plains All American

$24.57

-0.04 (-0.16%)

06:10
07/17/19
07/17
06:10
07/17/19
06:10
Initiation
Plains All American initiated  »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

ET

Energy Transfer LP

$14.94

0.03 (0.20%)

06:10
07/17/19
07/17
06:10
07/17/19
06:10
Initiation
Energy Transfer LP initiated  »

Energy Transfer LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$144.33

-0.72 (-0.50%)

06:09
07/17/19
07/17
06:09
07/17/19
06:09
Periodicals
Disney collects data on Disneyland guests via 'MagicBands,' Bloomberg reports »

Disney monitors usage of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

EPD

Enterprise Products

$30.32

0.005 (0.02%)

06:08
07/17/19
07/17
06:08
07/17/19
06:08
Initiation
Enterprise Products initiated  »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 31

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

06:07
07/17/19
07/17
06:07
07/17/19
06:07
Downgrade
CSX rating change  »

CSX downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 13

    Nov

MTSI

Macom

$15.55

0.01 (0.06%)

06:06
07/17/19
07/17
06:06
07/17/19
06:06
Upgrade
Macom rating change  »

Macom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$203.87

-0.06 (-0.03%)

06:05
07/17/19
07/17
06:05
07/17/19
06:05
Periodicals
Swiss group FDPIC says hasn't heard from Facebook over Libra, CNBC reports »

David Marcus, the head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.